Publications by authors named "David McCune"
A remote household-based approach to influenza self-testing and antiviral treatment.
Influenza Other Respir Viruses
July 2021
Article Synopsis
- - This study explored an at-home approach for diagnosing and treating influenza using home testing kits, telehealth consultations, and rapid delivery of antiviral medication to improve patient access and reduce delays in care.
- - Conducted during the 2019-2020 influenza season in Seattle, the pilot involved 124 households closely monitoring respiratory symptoms and utilizing home tests, resulting in a 72.7% sensitivity and 96.2% specificity for the tests.
- - With successful rapid delivery of medication (87.5% within 3 hours) following positive test results, the findings suggest that home-based diagnosis and treatment could be an effective strategy for managing influenza outbreaks.
Introduction: Denileukin diftitox, a chimeric protein, uses the cytocidal properties of diphtheria toxin to cells expressing interleukin-2 receptors. The aim of this study was to evaluate the efficacy and safety of denileukin diftitox in the treatment of advanced relapsed nonsmall cell lung cancer (NSCLC).
Patients And Methods: Multicenter phase II trial in patients with NSCLC with Eastern Cooperative Oncology Group PS 0-2, stage IIIB/IV at diagnosis, who had failed at least 1 previous chemotherapy regimen.
Article Synopsis
- The study investigated a peptide vaccine (IDM-2101) aimed at generating strong immune responses in cancer patients, specifically targeting non-small-cell lung cancer (NSCLC).
- The vaccine was administered to 63 HLA-A2 positive patients, who received 13 doses over two years while monitoring safety, immune response, and survival rates.
- Results indicated that IDM-2101 was generally well tolerated with minimal side effects, and patients exhibiting an immune response had significantly better survival rates, suggesting potential effectiveness of the vaccine.
Twenty medications are associated with drug-induced organizing pneumonia; however, thalidomide is not listed as a potential causative agent. Thalidomide (Thalomid, Celgene Corp., Summit, NJ), an angiogenesis inhibitor and immunomodulator that reduces tumor necrosis factor-alpha, is used for the treatment of multiple myeloma.
View Article and Find Full Text PDFPurpose: Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC). Targeted therapies may improve chemotherapy effectiveness without worsening toxicity. SGN-15 is an antibody-drug conjugate (ADC), consisting of a chimeric murine monoclonal antibody recognizing the Lewis Y (Le(y)) antigen, conjugated to doxorubicin.
View Article and Find Full Text PDF